Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

BRAF(V600E) is the most frequent oncogenic protein kinase mutation known. Furthermore, inhibitors targeting “active” protein kinases have demonstrated significant utility in the therapeutic repertoire against cancer. Therefore, we pursued the development of specific kinase inhibitors targeting B-Raf...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Tsai, James, Lee, John T., Wang, Weiru, Zhang, Jiazhong, Cho, Hanna, Mamo, Shumeye, Bremer, Ryan, Gillette, Sam, Kong, Jun, Haass, Nikolas K., Sproesser, Katrin, Li, Ling, Smalley, Keiran S. M., Fong, Daniel, Zhu, Yong-Liang, Marimuthu, Adhirai, Nguyen, Hoa, Lam, Billy, Liu, Jennifer, Cheung, Ivana, Rice, Julie, Suzuki, Yoshihisa, Luu, Catherine, Settachatgul, Calvin, Shellooe, Rafe, Cantwell, John, Kim, Sung-Hou, Schlessinger, Joseph, Zhang, Kam Y. J., West, Brian L., Powell, Ben, Habets, Gaston, Zhang, Chao, Ibrahim, Prabha N., Hirth, Peter, Artis, Dean R., Herlyn, Meenhard, Bollag, Gideon
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: National Academy of Sciences 2008
Konular:
Biological Sciences
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2268581/
https://ncbi.nlm.nih.gov/pubmed/18287029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0711741105
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller